Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Convulsive Therapy

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44379   clinical trials with a EudraCT protocol, of which   7391   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    50 result(s) found for: Convulsive Therapy. Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2021-002480-22 Sponsor Protocol Number: TAK-935-3001 Start Date*: 2021-07-22
    Sponsor Name:Takeda Development Center Americas, Inc
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Soticlestat as Adjunctive Therapy in Pediatric and Young Adul...
    Medical condition: Dravet Syndrome (DS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA IT (Completed) FR (Completed) ES (Completed) LV (Completed) GR (Completed) NL (Completed) BE (Completed) PL (Completed) HU (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-002484-25 Sponsor Protocol Number: TAK-935-2002(OV935) Start Date*: 2019-04-29
    Sponsor Name:Takeda Development Center Americas, Inc.
    Full Title: A PHASE 2, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TAK-935 (OV935) AS AN ADJUNCTIVE THERAPY IN PEDIATRIC PATIENTS WITH ...
    Medical condition: Epileptic Encephalitis: Dravet and Lennox Gastuat syndrome (LGS)
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-004396-12 Sponsor Protocol Number: 02 Start Date*: 2015-02-03
    Sponsor Name:Azienda Ospedaliero-Universitaria Meyer
    Full Title: Efficacy of ketamine in refractory convulsive status epilepticus in children: a multicenter, randomized, controlled, open-label, no-profit, with sequential design study.
    Medical condition: Refractory convulsive status epilepticus, defined as the recurrence of crisis for more than 60 minutes and / or drug-resistant I l and II line.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004852 10057955 Convulsive status epilepticus LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2015-004167-37 Sponsor Protocol Number: ZX008-1502 Start Date*: 2016-05-17
    Sponsor Name:Zogenix International Limited
    Full Title: A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of Two Fixed Doses of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and You...
    Medical condition: Dravet's syndrome
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) NO (Ongoing) DK (Completed) SE (Ongoing) ES (Completed) FR (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-000474-38 Sponsor Protocol Number: ZX008-1504 Start Date*: 2016-09-13
    Sponsor Name:Zogenix International Limited
    Full Title: A Multicenter, 2-Cohort Trial to First Assess the Pharmacokinetic and Safety Profile of a Single Dose of ZX008 (Fenfluramine Hydrochloride) Oral Solution When Added to Standard of Care (Cohort 1), ...
    Medical condition: Dravet's syndrome
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: NL (Completed) DE (Completed) GB (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2016-002804-14 Sponsor Protocol Number: ZX008-1503 Start Date*: 2016-11-08
    Sponsor Name:Zogenix International Limited, a wholly owned subsidiary of Zogenix Inc
    Full Title: An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children and Young Adults with Dravet Syndrome
    Medical condition: Seizures associated with Dravet syndrome
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10073682 Dravet syndrome LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) DE (Completed) IT (Completed) DK (Completed) ES (Ongoing) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-000396-14 Sponsor Protocol Number: 3/006/11 Start Date*: 2011-06-15
    Sponsor Name:University of Aberdeen [...]
    1. University of Aberdeen
    2. NHS Grampian
    Full Title: The use of Ketamine as an anaesthetic during electroconvulsive therapy (ECT) for depression: does it improve treatment outcome?
    Medical condition: Depression.
    Disease: Version SOC Term Classification Code Term Level
    13.1 10042613 - Surgical and medical procedures 10014404 Electroconvulsive therapy PT
    13.1 10037175 - Psychiatric disorders 10037175 Psychiatric disorders SOC
    13.1 10037175 - Psychiatric disorders 10012384 Depression endogenous LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003425-30 Sponsor Protocol Number: EPX-100-001 Start Date*: 2022-07-27
    Sponsor Name:Epygenix Therapeutics, Inc.
    Full Title: A 20-Week Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of EPX-100 (Clemizole HCl) as Adjunctive Therapy in Patients with Dravet Syndrome (ARGUS trial)
    Medical condition: Dravet Syndrome
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Temporarily Halted) HU (Trial now transitioned) PL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2009-017904-95 Sponsor Protocol Number: P09-005 Start Date*: 2010-06-28
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: Open-Label Extension Study to Evaluate the Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-Onset Seizures who had Participated in P09-004, a Randomized, Multicenter, Doub...
    Medical condition: Refractory partial-onset seizures with or without secondary generalization
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10056209 Partial seizures with secondary generalisation PT
    14.0 10029205 - Nervous system disorders 10034090 Partial seizures, complex LLT
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    14.0 10029205 - Nervous system disorders 10034091 Partial seizures, simple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-016996-31 Sponsor Protocol Number: P09-004 Start Date*: 2010-06-28
    Sponsor Name:Upsher-Smith Laboratories, Inc.
    Full Title: A Randomized, Multicenter, Double-Blind, Placebo–Controlled, Parallel-Group, Phase 3 Study to Evaluate the Efficacy and Safety of USL255 as Adjunctive Therapy in Patients with Refractory Partial-O...
    Medical condition: Refractory partial-onset seizures with or without secondary generalization
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10056209 Partial seizures with secondary generalisation PT
    14.0 10029205 - Nervous system disorders 10034090 Partial seizures, complex LLT
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10048674 Partial seizures with secondary generalization LLT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    14.0 10029205 - Nervous system disorders 10034091 Partial seizures, simple LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) ES (Completed) GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-004265-12 Sponsor Protocol Number: NBI-921352-FOS2022 Start Date*: 2021-12-21
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects with Focal Onset Seizures (FOS)
    Medical condition: Focal Onset Seizures (FOS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10016843 Focal seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) FR (Completed) HU (Prematurely Ended) ES (Ongoing) IT (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2005-001982-33 Sponsor Protocol Number: E2090-E044-401 Start Date*: 2005-09-05
    Sponsor Name:Eisai Limited
    Full Title: An open label study of Zonegran (zonisamide) in patients with partial onset seizures.
    Medical condition: Indicated as adjunctive therapy in the treatment of adult patients with partial seizures, with or without secondary generalisation.
    Disease: Version SOC Term Classification Code Term Level
    8.0 10061334 pt
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) SE (Completed) DK (Completed) FI (Completed) DE (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005440-25 Sponsor Protocol Number: SP904 Start Date*: 2009-02-16
    Sponsor Name:UCB BIOSCIENCES, Inc.
    Full Title: A Multicenter, Open-label Extension Trial to Assess the Long-term Use of Lacosamide Monotherapy and Safety of Lacosamide Monotherapy and Adjunctive Therapy in Subjects with Partial-onset Seizures
    Medical condition: Partial-onset seizures (with and without secondary generalization)
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    16.1 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) ES (Completed) AT (Completed) DK (Completed) PT (Not Authorised) IT (Completed) FR (Completed) DE (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-003161-40 Sponsor Protocol Number: A0081143 Start Date*: 2007-12-14
    Sponsor Name:Pfizer Inc,East 42nd street,New york, NY10017, USA
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, MULTI-CENTER, COMPARATIVE, FLEXIBLE DOSE TRIAL OF PREGABALIN VERSUS GABAPENTIN AS ADJUNCTIVE THERAPY IN SUBJECTS WITH PARTIAL SEIZURES
    Medical condition: Adjunctive treatment for subjects with partial seizures, with or without secondary generalization.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10061334 Partial seizures PT
    9.1 10056209 Partial seizures with secondary generalisation LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) ES (Completed) BG (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-000607-33 Sponsor Protocol Number: 200075 Start Date*: 2019-06-18
    Sponsor Name:GlaxoSmithKline S.A.
    Full Title: A Phase II, randomized, open-label, multicentre study to assess the reactogenicity, safety and immunogenicity of GSK’s paediatric Herpes Zoster subunit candidate vaccine (PED-HZ/su) when administer...
    Medical condition: Herpes Zoster Renal transplant Pediatric population
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-002142-31 Sponsor Protocol Number: 547-SSE-301 Start Date*: 2016-11-16
    Sponsor Name:Sage Therapeutics
    Full Title: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF SAGE-547 INJECTION IN THE TREATMENT OF SUBJECTS WITH SUPER-REFRACTORY STATUS EPILEPTICUS
    Medical condition: SUPER-REFRACTORY STATUS EPILEPTICUS (SRSE)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029205 - Nervous system disorders 10041962 Status epilepticus PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed) SE (Completed) DK (Completed) ES (Completed) NL (Completed) FI (Completed) HU (Completed) AT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-001433-39 Sponsor Protocol Number: NBI-921352-FOS2021 Start Date*: 2021-09-08
    Sponsor Name:Neurocrine Biosciences, Inc.
    Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of NBI-921352 as Adjunctive Therapy in Adult Subjects ...
    Medical condition: Focal Onset Seizures (FOS)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004852 10016843 Focal seizures LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) HU (Completed) FR (Completed) IT (Completed) BE (Completed) ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2014-003385-24 Sponsor Protocol Number: 2815 Start Date*: 2016-09-28
    Sponsor Name:GGZ inGeest, parner VUmc
    Full Title: The Recall-study: Rivastigmine for ECT-induced Cognitive Adverse effects in Late Life Depression: a multicenter, randomized, double-blind, placebo-controlled, crossover trial
    Medical condition: Interictal delirium during electric convulsive therapy- course
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2015-001324-36 Sponsor Protocol Number: 1042-900 Start Date*: 2015-06-05
    Sponsor Name:Marinus Pharmaceuticals, Inc.
    Full Title: A Multicenter, Open-Label Proof-of-Concept Trial of Ganaxolone in Children with PCDH19 Female Pediatric Epilepsy
    Medical condition: PCDH19 Female Pediatric Epilepsy (FPE)
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004852 10032062 Other forms of epilepsy, with intractable epilepsy LLT
    Population Age: Children, Under 18 Gender: Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2019-001633-14 Sponsor Protocol Number: CBD_DEE Start Date*: 2020-03-05
    Sponsor Name:IRCCS, OSPEDALE PEDIATRICO BAMBINO GESÙ DI ROMA
    Full Title: A single-centre, open-label pilot study to assess the efficacy and safety of CBD oral solution as an adjunctive treatment for pediatric subjects with Developmental and Epileptic Encephalopathy
    Medical condition: Developmental and Epileptic Encephalopathy (DEE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    20.0 10029205 - Nervous system disorders 10077380 Epileptic encephalopathy PT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Feb 09 05:18:16 CET 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA